Two Phase 1 studies of MDT-637 inhaled antiviral fusion inhibitor for the treatment of RSV infection have demonstrated that the drug is well tolerated and causes no significant changes in lung function, MicroDose Therapeutx has announced. The double-blind, randomized, placebo-controlled dose-ranging studies also showed that MDT-637 reached the respiratory tract at levels significantly higher than concentrations required to inhibit RSV in vitro while plasma level remained low.
MicroDose Senior Director, Product Commercialization Group, Robert Cook commented that the studies “provide important safety and pharmacokinetic data that will assist us in preparations for Phase 2 clinical trials anticipated to start in 2012.” The company is responsible for developing the inhalation powder, which was licensed by Gilead in 2011, through Phase 2a.
Read the MicroDose press release.
